Protein detail

CD2

T-cell surface antigen CD2 (Erythrocyte receptor) (LFA-2) (LFA-3 receptor) (Rosette receptor) (T-cell surface antigen T11/Leu-5) (CD antigen CD2)

Entry name
CD2
UniProt ID
EVMP score
0.50
Frequency
1
Transmembrane count
1
Protein classification
CD markersFDA approved drug targetsPredicted intracellular proteinsPredicted membrane proteins
EVMP score: annotation confidence score.
Extremely high >= 0.85High >= 0.70Medium >= 0.55Low >= 0.40
Basic Information
Protein Names
T-cell surface antigen CD2 (Erythrocyte receptor) (LFA-2) (LFA-3 receptor) (Rosette receptor) (T-cell surface antigen T11/Leu-5) (CD antigen CD2)
Protein Class
CD markersFDA approved drug targetsPredicted intracellular proteinsPredicted membrane proteins
Protein Function
  • CD markers
  • Predicted intracellular proteins
  • FDA approved drug targets:Biotech drugs
Transmembrane
210..235; Helical
Transmembrane Count
1
Entrez Gene Symbol
Gene Synonym
SRBC
Gene Description
CD2 molecule
Chromosome
1
Position
116754430-116769229
Frequency
1
EVMP Score
0.50
Fluorescence & Localization
CD2 fluorescence
Tissue Specificskin 1Cell SpecificDistal convoluted tubule cellsSingle-Nuclei Brain Specificchoroid plexus epithelial cellBlood Cell SpecificT-reg
Function & Pathway
Relations & Evidence

Enzyme-Mediated Modification

0 records.

Ligand-Receptor Signaling

50 records.

CategoryParentDatabaseTransmitterReceiverSecretedPlasma Membrane (Transmembrane)Plasma Membrane (Peripheral)
intracellularintracellularLOCATENoNoNoYesNo
intracellularintracellularGO_IntercellNoNoNoYesNo
intracellularintracellularOmniPathNoNoNoYesNo
cell_surface_ligandcell_surface_ligandconnectomeDB2020YesNoNoYesNo
cell_surface_ligandcell_surface_ligandBaccin2019YesNoNoYesNo
cell_surface_ligandcell_surface_ligandOmniPathYesNoNoYesNo
ig_likecell_adhesionHGNCYesYesNoYesNo
adhesionadhesionHGNCYesYesNoYesNo
cell_adhesioncell_adhesionCellinkerYesYesNoYesNo
cell_adhesioncell_adhesionZhong2015YesYesNoYesNo
Page 2 of 5PreviousNext

Regulatory Interaction Network

0 records.

Protein Complex Composition

130 records.

Component NameComponent Gene SymbolsComponent UniProt IDStoichiometryDatabaseDatabase IDsReferences
CARD19CCDC127CD244CHCHD3CHCHD6IMMTMTX2MTX3PDXDC1POMT1SAMM50O75431Q16891Q5HYI7Q6P996Q96BQ5Q96LW7Q9BRQ6Q9BZW8Q9NX63Q9Y512Q9Y6A10:0:0:0:0:0:0:0:0:0:0hu.MAP2
CARD19CD244CHCHD3CHCHD6IMMTMTX2MTX3SAMM50O75431Q16891Q5HYI7Q96LW7Q9BRQ6Q9BZW8Q9NX63Q9Y5120:0:0:0:0:0:0:0hu.MAP2
AAR2APEX1CD2BP2CHCHD3CRNKL1ECDKGD4PRPF19PRPF6PRPF8SNRNP200SNRNP40SNRNP70SNRPBSNRPCSNRPD1SNRPD2SNRPD3SNRPESRRM1O75643O94906O95400O95905P08621P09234P14678P27695P62304P62314P62316P62318P82909Q6P2Q9Q8IYB3Q96DI7Q9BZJ0Q9NX63Q9UMS4Q9Y3120:0:0:0:0:0:0:0:0:0:0:0:0:0:0:0:0:0:0:0Havugimana2012Havugimana2012:C_613
CD2BP2EFTUD2PRPF6PRPF8SNRNP200SNRNP40SNRPBSNRPD1SNRPD2SNRPD3SNRPESNRPFSNRPGTSSC4O75643O94906O95400P14678P62304P62306P62308P62314P62316P62318Q15029Q6P2Q9Q96DI7Q9Y5U21:1:1:1:1:1:1:1:1:1:1:1:1:1PDBPDB:8q7qPDB:8q7v
CD2BP2DDX23EFTUD2PRPF6PRPF8SNRNP200SNRPBSNRPD1SNRPD2SNRPD3SNRPESNRPFSNRPGO75643O94906O95400P14678P62304P62306P62308P62314P62316P62318Q15029Q6P2Q9Q9BUQ81:1:1:1:1:1:1:1:1:1:1:1:1PDBPDB:8q91
CD2BP2CDC5LEFTUD2PRPF38BPRPF8SF3A2SNRNP200SNRPA1SNRPBSNRPD1SNRPD2SNRPD3SNRPFSNRPGSRRM2O75643O95400P09661P14678P62306P62308P62314P62316P62318Q15029Q15428Q5VTL8Q6P2Q9Q99459Q9UQ351:1:1:1:1:1:1:1:1:1:1:1:1:1:1NetworkBlastCompleatCompleat:HC7088
CD2BP2CDC5LEFTUD2KHDRBS1PRPF8SF3A2SF3B2SNRNP200SNRPBSNRPD1SNRPD2SNRPD3SNRPFSNRPGSRRM2O75643O95400P14678P62306P62308P62314P62316P62318Q07666Q13435Q15029Q15428Q6P2Q9Q99459Q9UQ351:1:1:1:1:1:1:1:1:1:1:1:1:1:1NetworkBlastCompleatCompleat:HC9426
FANCD2FANCIUBCUSP1WDR48O94782P0CG48Q8TAF3Q9BXW9Q9NVI11:1:1:1:1PDBPDB:8a9kPDB:8a9j
FANCD2FANCIUBA52USP1WDR48O94782P62987Q8TAF3Q9BXW9Q9NVI11:1:1:1:1PDBPDB:7ay1
FANCD2LTN1O94822Q9BXW90:0hu.MAP2
Page 10 of 13PreviousNext

Isolation & Detection Technology

1 record.

EV Isolation MethodDetection MethodNumber of ReferencesReferences
Differential UltracentrifugationMass spectrometry123161513
Sequence, Structure & Domains

Sequences

Length
351
Mass
39,448
Sequence
MSFPCKFVASFLLIFNVSSKGAVSKEITNALETWGALGQDINLDIPSFQMSDDIDDIKWEKTSDKKKIAQFRKEKETFKEKDTYKLFKNGTLKIKHLKTDDQDIYKVSIYDTKGKNVLEKIFDLKIQERVSKPKISWTCINTTLTCEVMNGTDPELNLYQDGKHLKLSQRVITHKWTTSLSAKFKCTAGNKVSKESSVEPVSCPEKGLDIYLIIGICGGGSLLMVFVALLVFYITKRKKQRSRRNDEELETRAHRVATEERGRKPHQIPASTPQNPATSQHPPPPPGHRSQAPSHRPPPPGHRVQHQPQKRPPAPSGTQVHQQKGPPLPRPRVQPKPPHGAAENSLSPSSN

3D Structural Models

Turn
88..90; 139..142
Helix
62..64; 73..75; 99..101
Beta Strand
31..36; 41..43; 52..61; 67..71; 77..80; 84..86; 92..94; 103..111; 116..127; 134..138; 143..147; 155..162; 164..170; 172..175; 180..189; 194..203
3D Structure
NMR spectroscopy (3); X-ray crystallography (4)

Domain & Motif Annotations

Compositional Bias
243..262; Basic and acidic residues; 269..280; Polar residues; 326..338; Pro residues
Domain (FT)
25..128; Ig-like V-type; 129..209; Ig-like C2-type
Region
61..75; CD58 binding region 1; 106..120; CD58 binding region 2; 237..351; Disordered
Clinical Relevance
Disease Involvement
FDA approved drug targets
Related Diseases
Biomarker
Phase 2; Discontinued in Phase 2
Drug Targets
FDA approved drug targets
Interaction Protein
ENSG00000140368ENSG00000147010ENSG00000169217ENSG00000198087
Interaction Count
4
Interaction Dataset
intact_biogrid